Australian healthtech company Everlab has raised AUD $65 million in an oversubscribed Series A funding round to expand its preventative healthcare platform. The round was led by Airtree Ventures, with participation from Plural, Left Lane Capital, b2venture, and angel investors including Australian Test cricket captain Pat Cummins. The Melbourne-based company said the funding will support its push to make high-quality preventative care more accessible through a connected, data-driven model.
A Preventative Care Platform
Founded in 2023, Everlab is building a healthcare platform designed to shift primary care from treating illness after it appears to identifying risks earlier. The company combines diagnostics, clinician-led care, prescriptions, specialist referrals, wearable data, and AI-enabled support in one digital app. Its goal is to give patients a more complete and continuous view of their health, replacing fragmented services that often operate without shared records or coordinated follow-up.
Addressing Fragmented Healthcare
Everlab says the current healthcare system often leaves patients moving between separate providers, transactional telehealth services, and consumer health tools that do not connect meaningfully with clinical care. By integrating patient data across diagnostics, clinicians, specialists, and wearable devices, the company aims to create a longitudinal health record that can guide more targeted interventions. Co-founder and CEO Marc Hermann said Everlab was built to surface hidden health risks and coordinate the next steps, from screenings to personalised care plans.
Traction Across Australia and New Zealand
The company has already completed more than 40,000 consultations and supported over 20,000 individual patients, alongside corporate partners including Boston Consulting Group, BHP, and Bain & Company. Everlab says its platform integrates with more than 1,850 health provider locations, over 180 active clinicians, and more than 30 wearable devices. It also processes more than 200,000 health reports each month and has analysed over 21 million biomarker test results.
Clinical Findings and Patient Engagement
According to Everlab, more than 25% of its members have had findings flagged that were not previously identified through the existing healthcare system. Chief Medical Officer Dr Steven Lu said the company’s patient base reflects the broader Australian population, making long-term trust in handling health data central to its model. He added that Everlab aims to show that deeper patient engagement and stronger preventative care can improve outcomes while reducing lifetime healthcare costs.
Global Expansion Plans
The Series A round marks Everlab’s next stage of growth as it enters the global consumer healthcare market, which the company estimates at US$10 trillion. Its first international expansion target is the UK, where it plans to apply the model it has developed across Australia and New Zealand. The new capital will be used to strengthen Everlab’s clinical operations, technology infrastructure, and broader global rollout.
Investor Backing
Airtree partner John Henderson said the firm believes Everlab is building a long-term healthcare company with the potential to lead beyond Australia. He pointed to the company’s product quality and pace of growth as reasons behind Airtree’s investment. Plural partner Carina Namih said Everlab stands apart from companies that rely mainly on selling doctor appointments or lab tests because it is focused on interpreting and coordinating health data over time.
Everlab’s A$65 million Series A highlights growing investor interest in preventative, personalised, and AI-enabled healthcare models. By bringing diagnostics, clinicians, specialists, prescriptions, wearable data, and ongoing care coordination into one platform, the company is positioning itself as a new layer in primary healthcare. With fresh funding and plans to expand into the UK, Everlab is aiming to scale a model designed to detect disease risks earlier and help patients manage their health over the long term.